Richard E. Buller - Publications, H-index & Citations

Richard E. Buller

Pfizer

46H指数

171论文数

6.3K被引数

收录论文 29

发表时间

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma

FUTURE ONCOLOGY

IF2.6

2015-12-17

OAAI

English, Patricia A.; Williams, J. Andrew; Martini, Jean-Francois; Motzer, Robert J.; Valota, Olga; Buller, Richard E.

p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma

CANCER BIOLOGY & THERAPY

IF4.6

2014-10-28

OAAI

Sood, AK; Coffin, J; Jabbari, S; Buller, RE; Hendrix, MJC; Klingelhutz, A

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2013-09-06

PREAI

Fridlyand, Jane; Simon, Richard M.; Walrath, Jessica C.; Roach, Nancy; Buller, Richard; Schenkein, David P.; Flaherty, Keith T.; Allen, Jeff D.; Sigal, Ellen V.; Scher, Howard I.

Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination

CLINICAL CANCER RESEARCH

IF10.2

2006-06-15

111

OAAI

DiFeo, Analisa; Narla, Goutham; Hirshfeld, Jennifer; Camacho-Vanegas, Olga; Narla, Jyothsna; Rose, Stephen L.; Kalir, Tamara; Yao, Shen; Levine, Alice; Birrer, Michael J.; Bonome, Tomas; Friedman, Scott L.; Buller, Richard E.; Martignetti, John A.

E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor

ONCOGENE

IF7.3

2006-05-15

PREAI

DiFeo, A.; Narla, G.; Camacho-Vanegas, O.; Nishio, H.; Rose, S. L.; Buller, R. E.; Friedman, S. L.; Walsh, M. J.; Martignetti, J. A.

Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer

CLINICAL LUNG CANCER

IF3.3

2005-11-01

PREAI

Garst, Jennifer; Buller, Richard; Lane, Stephen; Crawford, Jeffrey

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer

CLINICAL CANCER RESEARCH

IF10.2

2005-05-16

PREAI

Goodheart, MJ; Ritchie, JM; Rose, SL; Fruehauf, JP; De Young, BR; Buller, RE

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: Results of a phase II trial

CLINICAL CANCER RESEARCH

IF10.2

2004-09-24

OAAI

Sood, AK; Lush, R; Geisler, JP; Shahin, MS; Sanders, L; Sullivan, D; Buller, RE; Sorosky, JI

Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma - Reply

CANCER

IF5.1

2004-04-26

OAAI

Geisler, JP; Buller, RE

Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma

CANCER

IF5.1

2003-09-25

102

OAAI

Geisler, JP; Goodheart, MJ; Sood, AK; Holmes, RJ; Hatterman-Zogg, MA; Buller, RE

Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

IF8.4

2003-07-01

PREAI

Bender, DP; Sorosky, JI; Buller, RE; Sood, AK

Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer adenovirus-p53基因治疗复发性卵巢癌的临床研究中p53基因转移和生物学活性的评估

CANCER GENE THERAPY

IF5

2003-03-14

PREAI

Wen, SF; Mahavni, V; Quijano, E; Shinoda, J; Grace, M; Musco-Hobkinson, ML; Yang, TY; Chen, YT; Runnenbaum, I; Horowitz, J; Maneval, D; Hutchins, B; Buller, R

Vascular endothelial growth factor and social support in patients with ovarian carcinoma

CANCER

IF5.1

2002-07-31

154

OAAI

Lutgendorf, SK; Johnsen, EL; Cooper, B; Anderson, B; Sorosky, JI; Buller, RE; Sood, AK

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 用SCH 58500替代Ad p53基因后复发性卵巢癌患者的长期随访

CANCER GENE THERAPY

IF5

2002-06-14

PREAI